The application of XXXX in regional chemotherapy.

@entity1 @entity5 @entity797 @entity221 @entity320
To evaluate the role of @entity221 combined with chemotherapy in the loco-regional treatment of @entity5 , a retrospective analysis was done with 228 limb @entity320 @entity1 treated with hyperthermic antiblastic perfusion (HAP). A series of treatment- and @entity5 -related prognostic factors was analyzed to establish their influence on @entity5 response, loco-regional control, and survival. Concerning @entity5 response, the logistic model showed that the number of lesions and the minimal @entity5 temperature (min T) maintained their individual predictive values (P < 0.000001 and P = 0.04, respectively). For loco-regional control, only the number of lesions had a significant predictive value. No direct correlation was found between the treatment-related variables and loco-regional control. However, the 5-year survival rate was significantly higher for @entity1 who achieved a complete response (CR) (51.5%, P = 0.0033) as compared to those who did not (33.3%), providing indirect evidence of the role of the treatment. Multivariate analysis showed that both disease-free and overall survival are strongly influenced by numerous clinical variables and the min T always maintained its significance. When analyzing the subgroup of 119 @entity1 evaluable for @entity5 response, the @entity797 model selected the @entity5 response as the dominant factor for both disease-free and overall survival. These data seem to demonstrate that the optimization of treatment parameters is crucial in determining the CR rate, which, in turn, positively affects the disease outcome. HAP is the treatment of choice for recurrent limb @entity320 , and @entity221 plays an important role in exploiting the efficacy of this technique.
